COMMUNIQUÉS West-GlobeNewswire

Crescent Biopharma Announces Grants of Inducement Awards
23/07/2026
WALTHAM, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma , Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies [...]
Immunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026
23/07/2026
DURHAM, N.C., July 23, 2026 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT ) today announced that it will report its financial results for the first quarter ended June 30, 2026 on Thursday, August 6, 2026 before the [...]
Cytokinetics to Announce Second Quarter Results on August 6, 2026
23/07/2026
SOUTH SAN FRANCISCO, Calif., July 23, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report second quarter results on August 6, 2026 at 4:00 PM Eastern Time. [...]
Roivant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026
23/07/2026
BASEL, Switzerland and LONDON and NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 6, 2026, to [...]
Progyny, Inc. Announces Details for Its Second Quarter 2026 Results Report
23/07/2026
NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women’s health and family building solutions, will report its financial results for the quarterly period ended June 30, 2026 [...]
Egg Medical annonce une nouvelle ère dans la sécurité en salle de fluoroscopie à la suite d’une déclaration de consensus conjointe
23/07/2026
Tandis que les principales sociétés médicales demandent l’adoption obligatoire de dispositifs de protection contre les rayonnements (ERPD), le système EggNest® Complete s’impose comme la solution définitive de [...]
CVRx to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call on August 6, 2026
23/07/2026
MINNEAPOLIS, July 23, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions [...]
MacroGenics Provides Clinical Update on Ongoing Phase 1 Study for MGC026
23/07/2026
Interim Phase 1 results accepted for poster presentation at ESMO Congress 2026 Achieved pre-specified Stage 1 response threshold in squamous cell carcinoma of the head and neck (SCCHN) cohort and enrolling Stage 2 per [...]
LUX MedSpa Brickell Announces Multiple 2025–2026 Industry Awards, Reinforcing Its Reputation as One of Miami's Most Reviewed Wellness Destinations
23/07/2026
Miami, FL, July 23, 2026 (GLOBE NEWSWIRE) -- LUX MedSpa Brickell , a luxury wellness destination inside the SLS LUX Hotel in Brickell, has received several industry awards in 2025 and 2026, adding to its growing [...]
Heartflow to Report Second Quarter 2026 Financial Results on August 13, 2026
23/07/2026
SAN FRANCISCO, July 23, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced it will release financial results for the [...]
Abivax renforce ses capacités commerciales avec des nominations stratégiques à des postes clés
23/07/2026
Abivax renforce ses capacités commerciales avec des nominations stratégiques à des postes clés Ces dirigeants expérimentés du secteur apportent plusieurs décennies d’expertise en stratégie commerciale, services aux [...]
Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM577a in H1069Q-mutated Wilson Disease
23/07/2026
-- FDA clearance of the IND, together with the previously cleared CTA, establishes a global Phase 1/2 clinical program for PM577a -- -- PM577a targets the H1069Q mutation in the ATP7B gene, the most prevalent WD-causing [...]
VYNE Therapeutics Provides Update Regarding Cash Dividend, Reverse Stock Split and Anticipated Timing of Closing of the Proposed Merger with Yarrow Bioscience
23/07/2026
NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that its previously announced special cash dividend (the “Cash Dividend”), declared in [...]
Guerbet : H1 2026 revenue.
23/07/2026
H1 2026 revenue H1 activity Revenue of €379.2m at 30 June 2026, nearly stable at CER 1 and on a like-for-like basis 2 (-0.1%) A 2.5% decline in Q2 at CER and on a like-for-like basis, marked by a solid recovery in the [...]
UPDATE - Omada Health to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 6, 2026
23/07/2026
SAN FRANCISCO, July 23, 2026 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, today announced that it will release its second quarter 2026 results on Thursday, August 6, [...]
OKYO Pharma Announces Purchase of Shares by Director
23/07/2026
LONDON and NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO ), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain ( [...]
Invitation to Idorsia's HY 2026 Financial Reporting webcast and conference call
23/07/2026
Idorsia will publish its Half Year 2026 Financial Reporting on Thursday July 30, at 07:00 CEST. An investor webcast and conference call will be held to discuss the results on the same day. Date: Thursday, July 30, 2026 [...]
OPKO Health to Report Second Quarter 2026 Financial Results on July 27, 2026
23/07/2026
MIAMI, July 23, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (OPKO) (NASDAQ: OPK), a fully-integrated healthcare company focused on delivering next-generation solutions for serious diseases across established global [...]
Guerbet : Chiffre d’affaires du 1er semestre 2026.
23/07/2026
Chiffre d’affaires du 1 er semestre 2026 Activité semestrielle Chiffre d’affaires au 30 juin 2026 de 379,2 M€, quasiment stable à TCC 1 et périmètre comparable 2 (-0,1%) Au deuxième trimestre, un repli de 2,5% à TCC et [...]

Pages